The company has announced research collaborations with academic institutions including Vanderbilt University Medical Center to advance immuno-oncology biomarker discovery. As a micro-cap OTC-traded biotech firm focused on protein analysis and cancer diagnostics, IMAC is positioned at the intersection of precision oncology and biomarker-driven treatment development.
Cyborg Score Rationale
IMAC faces significant headwinds as a micro-cap OTC stock trading below $0.10 with minimal market capitalization (~$217K as of March 2026). The company operates in a capital-intensive precision medicine space with limited scale and resources, though it has secured strategic partnerships with major medical centers.
Top Insights
Pivoted from traditional chiropractic services to precision medicine via Ignite Proteomics subsidiary (launched January 2025)
RPPA proteomic platform offers differentiation in cancer biomarker discovery but requires significant commercialization effort
Strategic partnerships with Vanderbilt and Inova Health suggest validation but minimal revenue traction
Extreme illiquidity and minimal market cap reflect lack of institutional adoption and funding constraints
Named Competitors
Tempus — AI-powered oncology diagnostics and precision medicine
Foundation Medicine — Comprehensive genomic profiling for cancer treatment
Guardant Health — Liquid biopsy and precision oncology diagnostics
Recent Developments
(January 2025) Launched Ignite Proteomics subsidiary focused on precision medicine
(February 2025) Completed acquisition of PLA Code 0249U for proteomic breast cancer assay
(August 2025) Announced research collaboration with Vanderbilt University Medical Center
(November 2024) Received Nasdaq deficiency notification; regained compliance through exception
Open the full interactive IMAC Holdings, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.